Roth Conference Archives - Page 62 of 117

MondayMar 12, 2018 8:30 pm

miRagen Therapeutics, Inc. (NASDAQ: MGEN) Starts Presentation at 30th Annual ROTH Conference

miRagen Therapeutics (NASDAQ: MGEN) is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs. The company’s MRG-106 is a clinical product candidate for the treatment of certain cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. The company is also developing MRG-110 for the treatment of heart failure and other ischemic disease. miRagen’s translational medicine strategy is…

MondayMar 12, 2018 8:30 pm

SuperCom Ltd. (NASDAQ: SPCB) Starts Presentation at 30th Annual ROTH Conference

SuperCom (NASDAQ: SPCB) has been a global provider of traditional and digital identity solutions since 1988, offering advanced safety, identification and security solutions to governments and both private and public organizations across the globe. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, the company has inspired governments and national agencies to design and issue secure multi-ID documents and strong digital identity solutions to citizens and visitors. SuperCom offers a distinctive, field-proven all-in-one identification, tracking and monitoring IoT hybrid suite along with cyber security products, a secured payments platform and…

MondayMar 12, 2018 8:00 pm

Jason Industries, Inc. (NASDAQ: JASN) Starts Presentation at 30th Annual ROTH Conference

Jason Industries (NASDAQ: JASN) is a globally diversified company comprised of four distinct manufacturing businesses that enhance end user’s comfort, safety and productivity. The company delivers finishing, components, seating and acoustics products and solutions to industrial, energy, heavy fabrication, off-highway equipment and transportation markets in the United States and internationally. Jason Industries is the parent company to a global family of manufacturers including Osborn, Metalex, Milsco, and Janesville Acoustics. Headquartered in Milwaukee, Wisconsin, Jason employs more than 4,200 people in 13 countries. For more information, visit the company’s website at www.jasoninc.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and…

MondayMar 12, 2018 8:00 pm

EnSync, Inc. (NYSE: ESNC) Starts Presentation at 30th Annual ROTH Conference

EnSync (NYSE: ESNC) is creating innovative distributed energy resource (“DER”) systems and Internet of energy (“IOE”) control platforms. The company uses an electrical infrastructure that prioritizes the use of all available resources, such as renewables, energy storage and the utility grid. As project developer, the company provides load analysis, system design consulting, and technical and financial modeling to ensure energy systems are sized and optimized to meet customers’ objectives. EnSync Energy’s IOE control platform adapts easily to ever-changing generation and load variables, as well as changes in utility prices and programs, ensuring the means to make or save money behind-the-meter,…

MondayMar 12, 2018 8:00 pm

ArQule, Inc. (NASDAQ: ARQL) Starts Presentation at 30th Annual ROTH Conference

ArQule (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The company’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need to significantly extend and improve the lives of patients. The company’s clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations. The company’s proprietary pipeline includes Derazantinib, Miransertib (ARQ 092), ARQ 751 and ARQ 761. Additionally, ArQule has advanced ARQ 531 to phase 1 for patients with B-cell malignancies refractory to other therapeutic…

MondayMar 12, 2018 8:00 pm

RESAAS Services, Inc. (CSE: RSS) (RSASF) Starts Presentation at 30th Annual ROTH Conference

RESAAS Services (CSE: RSS) (OTCQX: RSASF) is a cloud-based social business platform created to meet the needs of the real estate services industry. The company brings proprietary real-time technology into the real estate business and is helping transform the way real estate listing data flows among real estate agents, brokers, associations and MLSs. RESAAS is focused on providing a true place for all things real estate and uniting the global real estate industry. For more information, visit the company’s website at www.resaas.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a…

MondayMar 12, 2018 8:00 pm

Zix Corp. (NASDAQ: ZIXI) Starts Presentation at 30th Annual ROTH Conference

Zix (NASDAQ: ZIXI) is a provider of email security solutions, delivering a superior experience and easy-to-use solutions for email encryption and data loss prevention, advanced threat protection, archiving, and bring your own device (BYOD) mobile security. The nation’s most influential healthcare, finance and government institutions trust Zix. The company enables its customers to better secure their data and meet compliance needs by focusing on the protection of business communication. For more information, visit the company’s website at www.zixcorp.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via…

MondayMar 12, 2018 8:00 pm

Reed’s, Inc. (NYSE: REED) Starts Presentation at 30th Annual ROTH Conference

Reed’s (NYSE American: REED) owns one of the leading portfolios of handcrafted, natural beverages in the United States and has sold more than 500 million bottles. The company’s portfolio is sold in more than 20,000 retail doors across the natural, specialty, grocery, drug, club and mass channels throughout the country. Reed’s offers the No. 1 selling ginger beer brand in America and has led the ginger beer category for decades. The company’s award-winning ginger beers are distinctive in the category due to Reed’s proprietary hand-brewing process. The company also owns the Virgil’s line of flavored craft sodas, which is the…

MondayMar 12, 2018 8:00 pm

pSivida Corp. (NASDAQ: PSDV) Starts Presentation at 30th Annual ROTH Conference

pSivida (NASDAQ: PSDV) is a developer of sustained-release drug products and technologies for the treatment of eye diseases. Only four FDA-approved sustained-release treatments currently exist for back-of-the-eye diseases, and pSivida has developed three of the four. ILUVIEN®, a miniaturized insert for diabetic macular edema, is licensed to Alimera Sciences and currently sold in the United States and several EU countries. Retisert®, an implant for posterior uveitis, is licensed and sold by Bausch & Lomb. The company filed an NDA with the FDA in January 2018 for DurasertTM, its lead product candidate, which is being developed independently. For more information, visit…

MondayMar 12, 2018 8:00 pm

Lipocine, Inc. (NASDAQ: LPCN) Starts Presentation at 30th Annual ROTH Conference

Lipocine (NASDAQ: LPCN) is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Lipocine's clinical development pipeline includes three development programs. TLANDO, designed to help restore normal testosterone levels in hypogonadal men, was well tolerated and met the primary efficacy end-points in phase 3 testing and is currently under FDA review. LPCN 1111 is being…